Intellia Therapeutics, Inc., has announced a strategic partnership with ReCode Therapeutics. The partnership will seek to develop gene editing treatments for Cystic Fibrosis, though the financial terms remain undisclosed.
The joint initiative is projected to capitalize on Intellia's patented CRISPR-based gene editing technique, which includes its unique DNA writing technology. It will also make use of ReCode's Selective Organ Targeting lipid nanoparticle delivery platform in an effort to correct one or several Cystic fibrosis causing gene mutations.
Under the terms of the agreement, it will be Intellia's responsibility to devise the gene-editing strategy, and ReCode will take the lead in preclinical and clinical development as well as global commercialization.
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene, resulting in the build-up of thick mucus in the lungs, digestive system, and other organs. This can lead to life-threatening infections, respiratory failure, and other severe complications.
